HomeOpen Access NewsClinical Trials

Clinical Trials

First human trial of regenerative cell therapy for sensorineural hearing loss approved

The University of Sheffield announces approval of the first human trial testing regenerative cell therapy to treat sensorineural hearing loss, offering hope for restoring hearing function.

Moderna and Pfizer vaccines 90% effective in US real-world data

Real-world use of the Moderna and Pfizer vaccines in the United States reveals that both are working at 90% efficacy - with data pointing to one dose being capable of 80% protection.

Biosimilars: Improve access to treatment & reduce cost

Tore K Kvien & Guro L Goll argue that biosimilars are an opportunity for improving access to treatment & reducing cost and provide comment on the NOR-SWITCH study.

AstraZeneca vaccines made for UK could be kept for EU use only

EU leaders today (25 March) decided not to create an export ban for AstraZeneca vaccines made for the UK - but the feud between AstraZeneca and the bloc remains close to the surface of future discussions.

US trial finds AstraZeneca vaccine 100% effective against COVID death

In a study of over 32,000 people, a US trial found the AstraZeneca vaccine was 100% effective against deaths caused by COVID-19 - the vaccine did not show any connection to blood clots.

Polymers and polymer-based drug delivery in the treatment of dry eye disease

Professor Heather Sheardown, C20/20 Ophthalmic Materials Innovation Hub, Department of Chemical Engineering, McMaster University, explores how polymers can be used to treat dry eye disease.

European Medicines Agency say AstraZeneca does not cause blood clots

The safety committee of the European Medicines Agency said the investigation did not prove that AstraZeneca vaccinations cause blood clots - describing the possibility as an "extremely small likelihood".

COVID-19: The evolution of testing & sequencing

Novacyt Group, discusses the evolution of testing and sequencing during COVID-19 with a panel of distinguished speakers.

Birth control creates higher risk of blood clots than AstraZeneca vaccine

Currently, several EU countries are suspending use of the AstraZeneca vaccine due to reports of blood clot risks - in response, people are speaking out about the higher risk of blood clots posed by contraceptive pills used globally.

European Medicines Agency says AstraZeneca vaccine still safe to use

Over the weekend, the Republic of Ireland suspended their use of AstraZeneca due to reports of blood clots in Norway - in response, the European Medicines Agency (EMA) says the AstraZeneca vaccine is still safe to use.

Novavax 96.4% effective against the original COVID mutation

The US based vaccine appears to be 96.4% effective against the original COVID mutation, with 86% efficacy against the UK variant and only 55% against the South African variant.

Bharat Biotech COVID vaccine shows 81% efficacy at Phase Three

The Bharat Biotech COVID vaccine, COVAXIN, appears to be 81% efficient against the virus in Phase Three of clinical trials.

COVID vaccines for mutations will be given faster approval in the UK

Medical regulators will fast-track COVID vaccines for mutations, similar to how seasonal flu shots are developed and released.

The AstraZeneca vaccine is atleast 60% effective for people aged 70 and over

A study examining older people in the UK found that only one dose of the AstraZeneca vaccine is atleast 60% effective for people aged 70 and over.

Israel will now vaccinate Palestinians who have permits to work 

Israel faced international criticism on their refusal to vaccine Palestinians - now, the country will begin rolling out Pfizer shots to some Palestinians who have work permits.

FDA approves the Johnson & Johnson vaccine for use

The US Food and Drug Administration (FDA) approved the Johnson & Johnson vaccine, with an efficacy of 86%, as the next to be rolled out across the US.

The Pfizer vaccine is stopping 92% of severe COVID cases in Israel

Israel is currently leading the world in COVID vaccination, with real-world data to suggest that the Pfizer vaccine is working to stop 92% of severe COVID cases.

Advertisements


Latest Academic Articles

The latest academic articles from key research stakeholders